Item 8.01 Other Events.

On August 21, 2020, Adaptive Biotechnologies Corporation (the "Company") filed a prospectus supplement to its Form S-3 shelf registration statement, filed with the Securities and Exchange Commission on July 14, 2020. The prospectus supplement relates to the registration of up to 33,493,708 shares of the Company's common stock held by the selling shareholder identified in the prospectus supplement (the "Shares"). The Company will not offer any newly issued shares or receive any proceeds from the sale of the Shares by the selling shareholder, and the registration of the Shares for resale does not impact the total number of shares of the Company's common stock that are outstanding.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



                   Exhibit              Description
                   Number
                   5.1         Opinion of DLA Piper LLP (US)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses